MedTrace Logo

The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

NCT07064681 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-07-15

No results posted yet for this study

Summary

This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma, but refuse to receive neoadjuvant treatment will be asked again to participate this observational study retrospectively and prospectively. Participants will receive surgery and regular monitoring for 1 year. The purpose is to provide real-world cohort for comparison with the neoadjuvant cohort.

Conditions

  • Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Interventions

PROCEDURE

Surgery with and without the aid of Indocyanine Green (ICG)

Enrolled patients will receive surgery and be follow up for 2 years

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-05
Primary Completion
2025-12-17
Completion
2026-12-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07064681 on ClinicalTrials.gov